The Institutes at the NIH: NHLBIThe Institutes at the NIH: NHLBIKeith A. Horvath, MDKeith A. Horvath, MDDirector, Cardiothoracic Surgery Research Director, Cardiothoracic Surgery Research Program, NHLBI, NIHProgram, NHLBI, NIHChief, Cardiothoracic Surgery, NIH Heart Chief, Cardiothoracic Surgery, NIH Heart Center @ Suburban Hospital, Bethesda, MDCenter @ Suburban Hospital, Bethesda, MD

NHLBINHLBI

“ T H A T ’ S I T ? T H A T ’ S P E E R R E V I E W ? ”“ T H A T ’ S I T ? T H A T ’ S P E E R R E V I E W ? ”

Study Study SectionSectionYouYou

History of the NHLBIHistory of the NHLBIHistory of the NHLBIHistory of the NHLBI

• 1948 - Truman signs the National Health Act, 1948 - Truman signs the National Health Act, creating the NHIcreating the NHI

• 1949 - NHI Intramural Research Program 1949 - NHI Intramural Research Program • 1969 - Redesignated the NHLI1969 - Redesignated the NHLI• 1976 - “Blood” added1976 - “Blood” added

• 1948 - Truman signs the National Health Act, 1948 - Truman signs the National Health Act, creating the NHIcreating the NHI

• 1949 - NHI Intramural Research Program 1949 - NHI Intramural Research Program • 1969 - Redesignated the NHLI1969 - Redesignated the NHLI• 1976 - “Blood” added1976 - “Blood” added

Historical NHLBI TrialsHistorical NHLBI Trials Historical NHLBI TrialsHistorical NHLBI Trials

• 1950 - Combine with AHA to sponsor conference1950 - Combine with AHA to sponsor conference• 1972 - Nat’l High BP Education Program1972 - Nat’l High BP Education Program• 1981 - Beta-Blocker Heart Attack Trial1981 - Beta-Blocker Heart Attack Trial• 1983 - Coronary Artery Surgery Study1983 - Coronary Artery Surgery Study• 1984 - Lipid Research Prevention Trial1984 - Lipid Research Prevention Trial• 1985 - Thrombolysis in MI Trial1985 - Thrombolysis in MI Trial• 1990 - Human Gene Therapy1990 - Human Gene Therapy• 1991 - Studies of LV Dysfunction Trial1991 - Studies of LV Dysfunction Trial• 1995 - Bypass Angioplasty Revasc Initiative1995 - Bypass Angioplasty Revasc Initiative

• 1950 - Combine with AHA to sponsor conference1950 - Combine with AHA to sponsor conference• 1972 - Nat’l High BP Education Program1972 - Nat’l High BP Education Program• 1981 - Beta-Blocker Heart Attack Trial1981 - Beta-Blocker Heart Attack Trial• 1983 - Coronary Artery Surgery Study1983 - Coronary Artery Surgery Study• 1984 - Lipid Research Prevention Trial1984 - Lipid Research Prevention Trial• 1985 - Thrombolysis in MI Trial1985 - Thrombolysis in MI Trial• 1990 - Human Gene Therapy1990 - Human Gene Therapy• 1991 - Studies of LV Dysfunction Trial1991 - Studies of LV Dysfunction Trial• 1995 - Bypass Angioplasty Revasc Initiative1995 - Bypass Angioplasty Revasc Initiative

Historical NHLBI TrialsHistorical NHLBI Trials Historical NHLBI TrialsHistorical NHLBI Trials • 1999 - ARDS Network Study1999 - ARDS Network Study• 1999 - Early Revascularization for 1999 - Early Revascularization for

Cardiogenic ShockCardiogenic Shock• 2001 - Nat’l Emphysema Treatment Trial2001 - Nat’l Emphysema Treatment Trial• 2001 - REMATCH Trial2001 - REMATCH Trial• 2004 - Sudden Cardiac Death in HF Trial2004 - Sudden Cardiac Death in HF Trial• 2006 - SHOCK Trial2006 - SHOCK Trial• 2007 - Occluded Artery Trial (OAT)2007 - Occluded Artery Trial (OAT)• 2008 - Cardiothoracic Surgery Research Network2008 - Cardiothoracic Surgery Research Network

• 1999 - ARDS Network Study1999 - ARDS Network Study• 1999 - Early Revascularization for 1999 - Early Revascularization for

Cardiogenic ShockCardiogenic Shock• 2001 - Nat’l Emphysema Treatment Trial2001 - Nat’l Emphysema Treatment Trial• 2001 - REMATCH Trial2001 - REMATCH Trial• 2004 - Sudden Cardiac Death in HF Trial2004 - Sudden Cardiac Death in HF Trial• 2006 - SHOCK Trial2006 - SHOCK Trial• 2007 - Occluded Artery Trial (OAT)2007 - Occluded Artery Trial (OAT)• 2008 - Cardiothoracic Surgery Research Network2008 - Cardiothoracic Surgery Research Network

NHLBI Clinical TrialsNHLBI Clinical TrialsNHLBI Clinical TrialsNHLBI Clinical Trials

• EASTEAST• Infant Heart Surgery: Neuro/HCA Infant Heart Surgery: Neuro/HCA • CABG Patch TrialCABG Patch Trial• SHOCK TrialSHOCK Trial• Influence of CPB Temperature on CABG TrialInfluence of CPB Temperature on CABG Trial• REMATCH TrialREMATCH Trial• Tx of Post CABG Depression StudyTx of Post CABG Depression Study• NETTNETT

• EASTEAST• Infant Heart Surgery: Neuro/HCA Infant Heart Surgery: Neuro/HCA • CABG Patch TrialCABG Patch Trial• SHOCK TrialSHOCK Trial• Influence of CPB Temperature on CABG TrialInfluence of CPB Temperature on CABG Trial• REMATCH TrialREMATCH Trial• Tx of Post CABG Depression StudyTx of Post CABG Depression Study• NETTNETT

Surgical Trials1994-2009

Surgical Trials1994-2009

NHLBI Clinical TrialsNHLBI Clinical TrialsNHLBI Clinical TrialsNHLBI Clinical Trials

• BARI 2DBARI 2D $ 59 M$ 59 M• Surgical Treatment for Ischemic HF Surgical Treatment for Ischemic HF $ 37 M$ 37 M• FREEDOMFREEDOM $ 18 M$ 18 M• CT Surgery Research NetworkCT Surgery Research Network $ 18 $ 18 MM

• Moderate Ischemic Mitral RegurgitationModerate Ischemic Mitral Regurgitation• Severe Ischemic Mitral RegurgitationSevere Ischemic Mitral Regurgitation• Surgical Ablation for the Treatment of AFSurgical Ablation for the Treatment of AF• Post Cardiac Surgery Infection RegistryPost Cardiac Surgery Infection Registry

• BARI 2DBARI 2D $ 59 M$ 59 M• Surgical Treatment for Ischemic HF Surgical Treatment for Ischemic HF $ 37 M$ 37 M• FREEDOMFREEDOM $ 18 M$ 18 M• CT Surgery Research NetworkCT Surgery Research Network $ 18 $ 18 MM

• Moderate Ischemic Mitral RegurgitationModerate Ischemic Mitral Regurgitation• Severe Ischemic Mitral RegurgitationSevere Ischemic Mitral Regurgitation• Surgical Ablation for the Treatment of AFSurgical Ablation for the Treatment of AF• Post Cardiac Surgery Infection RegistryPost Cardiac Surgery Infection Registry

Surgical Trialsactive

Surgical Trialsactive

Office of the DirectorOffice of the Director

Division of Prevention & Population Sciences (DPPS)Division of Prevention & Population Sciences (DPPS)

Michael Laurer, Director

Diane Bild, Deputy Director

Epidemiology BranchEpidemiology Branch

Clinical Applications & Prevention BranchClinical Applications & Prevention Branch

Paul Sorlie, Branch Chief

Lawrence Fine, Branch Chief

Nancy Geller, Director

Office of Biostatistics ResearchOffice of Biostatistics Research

Women’s Health Initiative BranchWomen’s Health Initiative BranchJacques Rossouw, Director

Office of the DirectorOffice of the Director

Division of Cardiovascular Diseases (DCVD)Division of Cardiovascular Diseases (DCVD)

Sonia Skarlatos, Acting Director

Advanced Technologies & Surgery BranchAdvanced Technologies & Surgery Branch

Vascular Biology & Hypertension BranchVascular Biology & Hypertension Branch

Heart Failure & Arrhythmias BranchHeart Failure & Arrhythmias Branch

Atherothrombosis & Coronary Artery Disease BranchAtherothrombosis & Coronary Artery Disease Branch

Heart Developmental & Structural Diseases BranchHeart Developmental & Structural Diseases Branch

Dennis Buxton, Branch ChiefMarissa Miller, Deputy Branch Chief

Michael Domanski, Branch Chief

Ahmed Hasan, Acting Deputy Branch Chief

Gail Pearson, Branch ChiefCharlene Schramm, Deputy Branch Chief

Alice Mascette, Branch ChiefDavid Lathrop, Deputy Branch Chief

Eser Tolunay, Acting Branch Chief

Office of the DirectorOffice of the Director

Division of Blood Diseases and Resources (DBDR)Division of Blood Diseases and Resources (DBDR)

W. Keith Hoots, Director

George Nemo, Acting Deputy Director

Blood Diseases BranchBlood Diseases Branch

Transfusion Medicine and Cellular Therapeutics BranchTransfusion Medicine and Cellular Therapeutics Branch

Harvey Luksenburg, Chief

Simone Glynn, Chief

Rebecca Link, Acting Chief

Thrombosis and Hemostasis BranchThrombosis and Hemostasis Branch

Office of the DirectorOffice of the Director

Division of Lung Diseases (DLD)Division of Lung Diseases (DLD)

James Kiley, Director

Gail Weinmann, Deputy Director

Airway Biology and Disease BranchAirway Biology and Disease Branch

National Center on Sleep Disorders ResearchNational Center on Sleep Disorders Research

Thomas Croxton, Chief

Michael Twery, Director

Dorothy Gail, Chief

Lung Biology and Disease BranchLung Biology and Disease Branch

Office of the DirectorOffice of the Director

Division for the Application of Research Discoveries (DARD)Division for the Application of Research Discoveries (DARD)

Rob Fulwood, Acting Director

Enhanced Dissemination and Utilization BranchEnhanced Dissemination and Utilization Branch

Research Translation BranchResearch Translation Branch

Karen Donato, Acting Chief

Rob Fulwood, Acting Chief

Diane Striar, Acting Chief

Health Communications and Social Marketing BranchHealth Communications and Social Marketing Branch

Office of the DirectorOffice of the Director

Division of Extramural Research ActivitiesDivision of Extramural Research Activities

Stephen Mockrin, Director

Office of AcquisitionsOffice of Acquisitions

Office of Strategic and Innovative ProgramsOffice of Strategic and Innovative Programs

Office of Grants ManagementOffice of Grants Management

Office of Committee ManagementOffice of Committee Management

Office of Extramural Policy and ReviewOffice of Extramural Policy and Review

John Taylor, Director

Kathyrn Valeda, Director

Paul Velletri, Director

Suzanne White, Director

Robert Musson, Director

NHLBI Intramural ResearchNHLBI Intramural Research

– Translational Medicine BranchTranslational Medicine Branch– Hematology BranchHematology Branch– Pulmonary and Vascular Medicine BranchPulmonary and Vascular Medicine Branch– Cardiothoracic Surgery Research ProgramCardiothoracic Surgery Research Program

• LaboratoriesLaboratories

•Animal Medicine and SurgeryAnimal Medicine and Surgery

•Biochemistry and BiophysicsBiochemistry and Biophysics

•Cell Biology and Physiology Cell Biology and Physiology

•Genetics and Development Genetics and Development

•ImmunologyImmunology

University of Pennsylvania

Philadelphia, PA

NHLBI Obligations by Funding Mechanism: FY 2009NHLBI Obligations by Funding Mechanism: FY 2009NHLBI Obligations by Funding Mechanism: FY 2009NHLBI Obligations by Funding Mechanism: FY 2009

Funding Mechanism

Obligated Dollars*

(Thousands)

Percent of Total NHLBI Budget

Research Project Grants† $2,039,861 67.5%

SCORs/SCCORs 73,331 2.4

Sickle Cell Centers 13,567 0.5

Centers for AIDS Research 3,254 0.1

Other Research Grants 131,001 4.3

Research Careers Programs‡ 84,647 2.8

Training Programs 96,578 3.2

Research and Development Contracts 361,098 12.0

Intramural Research 181,734 6.1

Research Management and Support§ 114,128 3.8

Total Obligations $3,014,552 100%

* Excludes funds provided by other agencies by means of a reimbursable agreement.† Includes $76,341 for Small Business Innovation Research (SBIR) Grants/Small Business Technology

Transfer Grants (STTR).‡ Research Career Programs are a subset of Other Research Grants and are not added as a distinct funding

mechanism.§ Excludes OD and DIR research contracts, which are included in R&D contracts.

NHLBI Total Obligations by Budget Category: NHLBI Total Obligations by Budget Category: Fiscal Years 1999-2009 Fiscal Years 1999-2009 Current DollarsCurrent Dollars

NHLBI Competing Research Project Grant NHLBI Competing Research Project Grant Applications*: Fiscal Years 1999-2009Applications*: Fiscal Years 1999-2009

* Includes R01, R03, U01, P01, R15, R21, R29, and R37; R33 beginning in 2001; DP2 and U19 beginning in ’07; and DP1 and R00 beginning in ’08.

Percent of Reviewed Applications FundedPercent of Reviewed Applications Funded

22%22%

ResourcesResources

• Web HomeWeb Home

www.nhlbi.nih.govwww.nhlbi.nih.gov

• Fact Book Fact Book

www.nhlbi.nih.gov/about/factpdf.htmwww.nhlbi.nih.gov/about/factpdf.htm